Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
General Outlook
In simple terms, Regenicin, Inc. has 153.483 M shares that people are buying and selling right now.
Return on Investments
The company's asset efficiency, represented by a robust -0.080% return, is a testament to Regenicin, Inc.'s adeptness in optimizing resource deployment. Regenicin, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.164%. Furthermore, the proficiency of Regenicin, Inc. in capital utilization is underscored by a remarkable 0.150% return on capital employed.
Stock Prices
Regenicin, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.0021, while its low point bottomed out at $0.0021. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Regenicin, Inc.'s stock market.
